David Clynes
Overview
Explore the profile of David Clynes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
810
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goncalves T, Cunniffe S, Ma T, Mattis N, Rose A, Kent T, et al.
Nucleic Acids Res
. 2025 Feb;
53(4).
PMID: 39970292
The alternative lengthening of telomeres (ALT) pathway is a telomerase-independent mechanism for immortalization in cancer cells and is commonly activated in low-grade and high-grade glioma, as well as osteosarcoma. The...
2.
Goncalves T, Cunniffe S, Ma T, Mattis N, Rose A, Kent T, et al.
Nucleic Acids Res
. 2025 Feb;
53(4).
PMID: 39921567
The alternative lengthening of telomeres (ALT) pathway is a telomerase-independent mechanism for immortalization in cancer cells and is commonly activated in low-grade and high-grade glioma, as well as osteosarcoma. The...
3.
Goncalves T, Bhatnagar H, Cunniffe S, Gibbons R, Rose A, Clynes D
Open Biol
. 2024 Dec;
14(12):240205.
PMID: 39657822
Approximately 10-15% of human cancers are telomerase-negative and maintain their telomeres through a recombination-based process known as the alternative lengthening of telomeres (ALT) pathway. Loss of the alpha-thalassemia/mental retardation, X-linked...
4.
Kliszczak M, Moralli D, Jankowska J, Bryjka P, Subha Meem L, Goncalves T, et al.
Front Cell Dev Biol
. 2023 Jun;
11:1175069.
PMID: 37342232
Hereditary fibrosing poikiloderma (HFP) is a rare human dominant negative disorder caused by mutations in the gene that encodes a nuclear trypsin-like serine protease. HFP patients present with symptoms including...
5.
Rose A, Goncalves T, Cunniffe S, Geiller H, Kent T, Shepherd S, et al.
Nucleic Acids Res
. 2023 Mar;
51(13):6509-6527.
PMID: 36940725
Telomere maintenance is a hallmark of malignant cells and allows cancers to divide indefinitely. In some cancers, this is achieved through the alternative lengthening of telomeres (ALT) pathway. Whilst loss...
6.
Kent T, Clynes D
Genes (Basel)
. 2021 Nov;
12(11).
PMID: 34828344
The study of the molecular pathways underlying cancer has given us important insights into how breaks in our DNA are repaired and the dire consequences that can occur when these...
7.
Kent T, Gracias D, Shepherd S, Clynes D
Front Oncol
. 2020 Feb;
9:1518.
PMID: 32039009
Achieving replicative immortality is a crucial step in tumorigenesis and requires both bypassing cell cycle checkpoints and the extension of telomeres, sequences that protect the distal ends of chromosomes during...
8.
Nguyen D, Voon H, Xella B, Scott C, Clynes D, Babbs C, et al.
EMBO Rep
. 2017 May;
18(6):914-928.
PMID: 28487353
ATRX is a chromatin remodelling factor found at a wide range of tandemly repeated sequences including telomeres (TTAGGG) ATRX mutations are found in nearly all tumours that maintain their telomeres...
9.
Clynes D, Jelinska C, Xella B, Ayyub H, Scott C, Mitson M, et al.
Nat Commun
. 2015 Jul;
6:7538.
PMID: 26143912
Fifteen per cent of cancers maintain telomere length independently of telomerase by the homologous recombination (HR)-associated alternative lengthening of telomeres (ALT) pathway. A unifying feature of these tumours are mutations...
10.
Chen E, Ahn J, Massie C, Clynes D, Godfrey A, Li J, et al.
Proc Natl Acad Sci U S A
. 2014 Oct;
111(42):15190-5.
PMID: 25288776
Cancers result from the accumulation of genetic lesions, but the cellular consequences of driver mutations remain unclear, especially during the earliest stages of malignancy. The V617F mutation in the JAK2...